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Abstract
Evaluation of the association between single-nucleotide polymorphisms (SNPs) and disease
outcomes is widely used to identify genetic risk factors for complex diseases. Although this analysis
paradigm has made significant progress in many genetic studies, many challenges remain, such as the
requirement of a large sample size to achieve adequate power. Here we use rheumatoid arthritis
(RA) as an example and explore a new analysis strategy: pathway-based analysis to search for
related genes and SNPs contributing to the disease.
We first propose the application of measure of explained variation to quantify the predictive ability
of a given SNP. We then use gene set enrichment analysis to evaluate enrichment of specific
pathways, where pathways, are considered enriched if they consist of genes that are associated
with the phenotype of interest above and beyond is expected by chance. The results are also
compared with score tests for association analysis by adjusting for population stratification.
Our study identified some significantly enriched pathways, such as “cell adhesion molecules,” which
are known to play a key role in RA. Our results showed that pathway-based analysis may identify
other biologically interesting loci (e.g., rs1018361) related to RA: the gene (CTLA4) closest to this
marker has previously been shown to be associated with RA and the gene is in the significant
pathways we identified, even though the marker has not reached genome-wide significance in
univariate single-marker analysis.
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Rheumatoid arthritis (RA) is the most common systemic
autoimmune disease characterized by chronic, destruc-
tive, and debilitating inflammation of joints and extra-
articular tissues [1]. The disease affects 1% of the adult
population worldwide and is significantly more pre-
valent in women (3 to 1 ratio) than men. It is believed
that the contribution of individual genes to complex
diseases such as RA, is generally modest and difficult to
detect due to inadequate sample sizes compared with the
large number of variables being tested for association.
Currently, the literature on genome-wide association
studies is focused on testing single-nucleotide poly-
morphisms (SNPs) for association using standard test
statistic (for example, chi-square test statistic). The
difficulty in detecting genes of modest effects may be
one potential explanation for inconsistent results often
seen in genetic association studies [2]. In a recent
genome-wide study of RA with a relatively large sample
size, Plenge et al. [3] identified a genome-wide sig-
nificant association signal on chromosome 9 close to
TRAF1 and C5 in addition to confirming known genes
related to RA (e.g., HLA-DRB1 in major histocompat-
ibility complex (MHC) region and PTPN22) [3].
In this paper, we propose a pathway-based approach to
study sets of genes. The motivation for this is the belief
that the mechanism of a complex disease such as RA may
not be described fully by looking at gene-by-gene
comparisons alone. Gene set analysis has been widely
used in studies involving gene expression data; however,
there are only a few such studies in a genome-wide
association setting. We also propose two measures of
explained variation that are appropriate for binary
outcomes and summarize these measurements over all
SNPs in and around a particular gene.
Materials and methods
Data description
The provided data is a subset of the Stage 1 genome-wide
association study of RA previously analyzed by Plenge
et al. [3]. After removing duplicated and contaminated
samples, there were 868 cases from the North American
Rheumatoid Arthritis Consortium (NARAC) and 1194
controls on which 545,080 SNPs had been genotyped.
Quality control
The SNPs and samples fulfilling the following quality
control requirements were included in our analysis: 1)
call rate: SNP and sample call rates > 95%; 2) Hardy-
Weinberg equilibrium: false-discovery rate (FDR) level in
testing for Hardy-Weinberg equilibrium among controls
> 0.2; 3) minor allele count > 10 copies, which is
equivalent to a minor allele frequency of 0.24% (i.e, 10/
(2 × 2062) = 0.24%). A total of 490,000 SNPs and 2062
samples met our quality control criteria and were used
for further analysis.
Adjustment for population stratification
It has been indicated that this data set is affected by
population stratification, and this may lead to mislead-
ing association results if not taken into account. We
followed an approach proposed by Price et al. [4] to
adjust for population stratification. The steps involved
can be summarized as follows: i) Using the SNP set
remaining after applying our quality control criteria, we
first removed SNPs in the MHC region (29-34 Mb on
chromosome 6) and on the sex chromosomes. ii) For the
remaining SNPs, we pruned them based on linkage
disequilibrium using PLINK [5]. iii) This left around 220
k SNPs for which we calculated genome-wide pair-wise
identity-by-state similarity matrix followed by multi-
dimensional scaling analysis on the identity-by-state-
based distance matrix. iv) We selected 15 significant
principal coordinates (PCs) with p-value < 0.001. v)
These 15 significant PCs were used in subsequent
association analyses. It should be noted that these
steps were only applied to select these 15 significant
PCs. In the subsequent association analyses, we used all
SNPs and samples that passed the quality control
criteria.
Univariate SNP association test
We performed score tests for association between RA
status in patients and their genotypes, and adjusted for
possible population stratification using the significant
principal components. We used the ‘egscore’ function in
GenABEL R package [6], in which the population
stratification method proposed by Price et al. [4] is
implemented. We obtained the corresponding p-value
and chi-square value for each SNP.
Measures of explained variation
For a given SNP, let (yi, xi), i = 1, ..., n denote its n
samples/observations, where yi denotes the outcome of
the observation i (in this study, yi = 1 if the subject is a
case and 0 otherwise) and xi denotes the genotype
(coded as 0, 1, 2, corresponding to AA, AB, and BB) of
the ith observation. We consider two measures of
explained variation for binary outcomes [7]. These
measures are based on direct and indirect estimates of
predictive accuracy. The direct measure is based on
residual from the fit and the indirect index is related to a
standard measure of information. Let the estimates from
a l o g i s t i c mod e l w i t hou t a c o v a r i a t e b e
Pr{ }y p yi
yi
n= ≡ = =
∑1 and the estimates from a
model with covariate xi be Pr{ | }y x pi i i= =1  . Define
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ˆ | ˆ |D n y px i i= −
− ∑1 and ˆ | ˆ |D n y px i i= −− ∑1 , and the
explained variation based on the direct estimates
becomes EV D D Ddirect x= − ×( ) / %   100 . Similarly, let
D p p= −2 1( ) and D n p px i i= −− ∑2 11 ˆ ( ˆ ) , then the
explained variation based on indirect estimates is
calculated as EV D D Dindirect x= − ×( ) / %   100 . We denote
these two approaches as DirEV and IndirEV, respectively.
In the models which include principal components to
adjust for population stratification, the explained varia-
tion attributable to each SNP were obtained.
Pathway-based analysis
We summarize the steps for our method as follows
(adapted from Wang et al. [8]):
1. Obtain test/summary statistic
For each SNP, we computed one of the following:
measure of explained variation and univariate SNP
association test (c2) where population stratification is
adjusted for by including 15 PCs.
2. Map SNPs to genes
We obtained the nearest gene name for each SNP from
the Illumina SNP annotation file (HumanHap650Yv3_
Gene_Annotation.txt, available from https://icom.
illumina.com/) based on physical distance. The
490,000 SNPs were mapped to 16,500 genes.
3. Aggregate test/summary statistic
For each gene, we obtained an aggregate summary
measure or test statistic based on individual values
(from Step 1 above) for SNPs assigned to this gene
(Step 2). Here we used the maximum summary measure or
maximum test statistic over all SNPs mapped to the gene.
4. The aggregated summary measure or test statistics
were used to evaluate the significance of predefined gene
sets/pathways [9] based on the gene set enrichment
analysis (GSEA) method [10]. Here we used the c2
curated gene sets, which are obtained from online
pathway databases, citation in PubMed [9], and knowl-
edge of domain experts and included 1900 gene sets
collected from canonical pathways, chemical and genetic
perturbations, BioCarta pathways, GeneMAPP [11], and
KEGG [12]. A Kolmogorov-Smirnov non-parametric
rank statistic was performed using the GseaPreranked
tool included in the GSEA software. Gene sets were
ranked by their FDR q-value, where the q-value of a test
measures the proportion of false positives incurred
(FDR) when that particular test is called significant.
The empirical null distribution was obtained using 1000
random permutations. We defined a given gene set as
significantly enriched in the data if it has FDR q-value of
less than 0.05.
Results
For the 1900 gene sets that we evaluated, all three
methods (Chi-Sq, DirEV and IndirEV) identified 10 gene
sets that have FDR q-value of less than 0.05. Table 1
shows these ten significantly enriched gene sets/path-
ways identified by GSEA for each of the three methods.
As seen from Table 1, the ten significantly enriched
pathways for the three summary methods are the same.
The pathways identified using DirEv and IndirEV have
similar FDR q-value and ranks. The FDR q-value results
based on the c2 tests are slightly different from those
based on DirEV and IndirEV.
As discussed before, there are few potential genes
associated with RA: PTPN22 on chromosome 1,
HLA_DRB1 on the MHC region on chromosome 6, and
TRAF1/C5 on chromosome 9. However, PTPN22 and
TRAF1/C5 were not in any of the ten significantly
enriched gene sets. Therefore, we further evaluated the
distributions of genes and SNPs in the MHC region
compared with the rest of the genome (those not in MHC
region) in these ten gene sets/pathways (Table 2). To do
this, we defined the MHC region as 29-34 Mb on
chromosome 6. The region is defined based on the
results shown in Supplementary Table 1B of Plenge et al.
[3], that is, SNPs that have p-value < 0.0001. We found
561 SNPs in the defined MHC region with p-value
< 0.0001; and 227 genes in the region using BioMart [13].
Table 2 shows the distribution of these genes and SNPs
in the defined MHC region and other genes and SNPs
with p-value < 0.0001 in the rest of the genome in the 10
gene sets/pathways. It can be seen the MHC region is
enriched for genes from the following three gene sets:
“Hsa04612 Antigen Processing and Presentation,”
“Hsa04940 Type I Diabetes Mellitus,” and “Hsa04514
Cell Adhesion Molecule.” There were 22 HLA-related
genes in common among these three gene sets. Of these,
20 were found in the defined MHC region. Five SNPs
with p-value < 0.0001 were present in these three gene
sets in the MHC region. Interestingly, one SNP
(rs1018361) with p-value of 2.6 × 10-5 on chromosome
2 was present in one of the three gene sets ("Hsa04514
Cell Adhesion Molecule”) in the rest of genome (the
region excluding MHC region) while the other two gene
sets had no significant SNPs in the rest of the genome.
The significant SNP on chromosome 2 (rs1018361) may
be of interest for further investigation because the closest
gene (CTLA4) to this SNP shares the same pathway as
those genes containing the MHC region. Moreover,
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previous association study showed that RA is associated
with CTLA4 [2]. Similarly, the cell adhesion molecules
(proteins) may have an important role in regulation of
the RA development than other tested pathways. As
shown in Table 2, both genes and SNPs with p-value
< 0.0001 in the pathway (cell adhesion molecule) are
found in both theMHC region and the rest of the genome,
while other significant pathways have SNPs with p-value <
0.0001 only in the MHC region or are not found in either
the MHC region or the rest of the genome.
Conclusion
Overall, using a pathway-based analysis, we found some
of the significant gene sets/pathways were enriched in
the well known MHC region associated with RA.
However, some of the loci that have been reported to
be related to RA, such as PTPN22 and TRAF1/C5, were
not found to be enriched in any of the gene sets/
pathways we identified as significant. Our results also
showed that pathway-based analysis may identify other
RA-related loci (e.g., rs1018361) because the gene
(CTLA4) closest to this SNP has previously been shown
to be associated with RA and the significant pathways
identified here contained this gene.
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Table 1: Significant pathways identified by three test statistic methods
c2 DirEV IndirEV
Gene sets/pathways No. genesa Rankb FDR q-value Rank FDR q-value Rank FDR q-value
Hsa04612 antigen processing and presentation 57 1 <1*10-8 1 <1*10-8 1 <1*10-8
Hsa04940 Type I diabetes mellitus 40 2 <1*10-8 2 <1*10-8 2 <1*10-8
Wieland hepatitis B-induced 87 3 <1*10-8 3 0.004 3 0.001
Ctla4 pathway 18 4 6*10-5 6 0.006 4 0.003
Ami pathway 22 5 0.01 7 0.006 10 0.015
Csk pathway 22 6 0.01 10 0.011 7 0.012
Sana Ifng endothelial up 67 7 0.011 8 0.006 9 0.013
Th1th2 pathway 17 8 0.011 9 0.009 8 0.013
Inflam pathway 28 9 0.012 4 0.005 6 0.006
Hsa04514 cell adhesion molecule 115 10 0.02 5 0.005 5 0.004
aNumber of genes found in our data. (The actual number of genes defined in the set is larger than these numbers.)
bThe rank is based on the FDR q-value for all 1,900 tested gene sets in each method.
Table 2: Distribution of selected genes and SNPs in each of the two regions and nine gene sets/pathways
MHC region
(Chr 6, 29-34 Mba)
Rest of genome
Gene sets/pathways No. genes %b #SNPs No. genes %a No. SNPs
Hsa04612 antigen processing and Presentation 24 42.1 5 33 57.9 0
Hsa04940 Type I Diabetes Mellitus 22 55.0 6 18 45.0 0
Wieland hepatitis B-iInduced 15 17.2 4 72 82.8 0
Ctla4 pathway 2 11.1 0 16 88.9 1
Ami pathway 2 9.1 0 20 90.9 0
Csk pathway 2 9.1 0 20 90.9 0
Sana Ifng endothelial up 11 16.4 2 56 83.6 0
Th1th2 pathway 2 11.8 0 15 88.2 0
Inflam pathway 4 14.3 2 24 85.7 0
Hsa04514 cell adhesion molecule 20 17.4 5 95 82.6 1
aThis region covers approximately 0.2% the whole genome
bThe percentage of genes in a given gene set that were found in the region
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